127 related articles for article (PubMed ID: 22231447)
21. Putting the BRK on breast cancer: From molecular target to therapeutics.
Ang HL; Yuan Y; Lai X; Tan TZ; Wang L; Huang BB; Pandey V; Huang RY; Lobie PE; Goh BC; Sethi G; Yap CT; Chan CW; Lee SC; Kumar AP
Theranostics; 2021; 11(3):1115-1128. PubMed ID: 33391524
[TBL] [Abstract][Full Text] [Related]
22. Identification of Signatures of Prognosis Prediction for Melanoma Using a Hypoxia Score.
Shou Y; Yang L; Yang Y; Zhu X; Li F; Xu J
Front Genet; 2020; 11():570530. PubMed ID: 33133157
[TBL] [Abstract][Full Text] [Related]
23. Targeting protein tyrosine kinase 6 in cancer.
Gilic MB; Tyner AL
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188432. PubMed ID: 32956764
[TBL] [Abstract][Full Text] [Related]
24. Long Noncoding RNA LINC01485 Promotes Tumor Growth and Migration via Inhibiting EGFR Ubiquitination and Activating EGFR/Akt Signaling in Gastric Cancer.
Zhou J; Wu L; Li W; Xu X; Ju F; Yu S; Guo J; Li G; Shi J; Zhou S
Onco Targets Ther; 2020; 13():8413-8425. PubMed ID: 32904620
[TBL] [Abstract][Full Text] [Related]
25. Protein tyrosine kinase 6 signaling in prostate cancer.
Alwanian WM; Tyner AL
Am J Clin Exp Urol; 2020; 8(1):1-8. PubMed ID: 32211448
[TBL] [Abstract][Full Text] [Related]
26. Vemurafenib Inhibits Active PTK6 in
Wozniak DJ; Hitchinson B; Gilic MB; Bie W; Gaponenko V; Tyner AL
Mol Cancer Ther; 2019 May; 18(5):937-946. PubMed ID: 30926642
[TBL] [Abstract][Full Text] [Related]
27. Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
Regan Anderson TM; Ma S; Perez Kerkvliet C; Peng Y; Helle TM; Krutilina RI; Raj GV; Cidlowski JA; Ostrander JH; Schwertfeger KL; Seagroves TN; Lange CA
Mol Cancer Res; 2018 Nov; 16(11):1761-1772. PubMed ID: 29991529
[TBL] [Abstract][Full Text] [Related]
28. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
Meng S; Wang G; Lu Y; Fan Z
Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
[TBL] [Abstract][Full Text] [Related]
29. STAP-2 protein promotes prostate cancer growth by enhancing epidermal growth factor receptor stabilization.
Kitai Y; Iwakami M; Saitoh K; Togi S; Isayama S; Sekine Y; Muromoto R; Kashiwakura JI; Yoshimura A; Oritani K; Matsuda T
J Biol Chem; 2017 Nov; 292(47):19392-19399. PubMed ID: 28986450
[TBL] [Abstract][Full Text] [Related]
30. The associated pyrazolopyrimidines PP1 and PP2 inhibit protein tyrosine kinase 6 activity and suppress breast cancer cell proliferation.
Shim HJ; Kim HI; Lee ST
Oncol Lett; 2017 Mar; 13(3):1463-1469. PubMed ID: 28454278
[TBL] [Abstract][Full Text] [Related]
31. The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR.
Mohyeldin MM; Akl MR; Siddique AB; Hassan HM; El Sayed KA
Biochem Pharmacol; 2017 Feb; 126():51-68. PubMed ID: 27940262
[TBL] [Abstract][Full Text] [Related]
32. PTK6 promotes hepatocellular carcinoma cell proliferation and invasion.
Chen X; Song B; Lin Y; Cao L; Feng S; Zhang L; Wang F
Am J Transl Res; 2016; 8(10):4354-4361. PubMed ID: 27830019
[TBL] [Abstract][Full Text] [Related]
33. Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer.
Regan Anderson TM; Ma SH; Raj GV; Cidlowski JA; Helle TM; Knutson TP; Krutilina RI; Seagroves TN; Lange CA
Cancer Res; 2016 Mar; 76(6):1653-63. PubMed ID: 26825173
[TBL] [Abstract][Full Text] [Related]
34. Sphingosine-1-phosphate induces the migration of thyroid follicular carcinoma cells through the microRNA-17/PTK6/ERK1/2 pathway.
Zhao S; Li J
PLoS One; 2015; 10(3):e0119148. PubMed ID: 25748447
[TBL] [Abstract][Full Text] [Related]
35. Pathways driving the endocytosis of mutant and wild-type EGFR in cancer.
Hampton KK; Craven RJ
Oncoscience; 2014; 1(8):504-12. PubMed ID: 25594057
[TBL] [Abstract][Full Text] [Related]
36. The TWEAK Receptor Fn14 Is an Src-Inducible Protein and a Positive Regulator of Src-Driven Cell Invasion.
Cheng E; Whitsett TG; Tran NL; Winkles JA
Mol Cancer Res; 2015 Mar; 13(3):575-83. PubMed ID: 25392346
[TBL] [Abstract][Full Text] [Related]
37. Downregulated expression of PTK6 is correlated with poor survival in esophageal squamous cell carcinoma.
Chen YF; Ma G; Cao X; Huang ZL; Zeng MS; Wen ZS
Med Oncol; 2014 Dec; 31(12):317. PubMed ID: 25377660
[TBL] [Abstract][Full Text] [Related]
38. PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors.
Peng M; Emmadi R; Wang Z; Wiley EL; Gann PH; Khan SA; Banerji N; McDonald W; Asztalos S; Pham TN; Tonetti DA; Tyner AL
Oncotarget; 2014 Aug; 5(15):6038-48. PubMed ID: 25153721
[TBL] [Abstract][Full Text] [Related]
39. Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy.
Hussain HA; Harvey AJ
World J Clin Oncol; 2014 Aug; 5(3):299-310. PubMed ID: 25114846
[TBL] [Abstract][Full Text] [Related]
40. Cytoplasmic retention of a nucleocytoplasmic protein TBC1D3 by microtubule network is required for enhanced EGFR signaling.
He Z; Tian T; Guo D; Wu H; Chen Y; Zhang Y; Wan Q; Zhao H; Wang C; Shen H; Zhao L; Bu X; Wan M; Shen C
PLoS One; 2014; 9(4):e94134. PubMed ID: 24714105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
